Harbin medicine movement! 160 million purchase of six products of foreign enterprises
-
Last Update: 2018-10-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Yesterday, the 12th meeting of the 8th board of directors of Harbin Pharmaceutical Group Co., Ltd was notified in writing, and the meeting was held in the form of communication meeting on October 22, 2018 There were 7 directors who should participate in the voting, and 7 directors actually participated in the voting The meeting deliberated and passed the proposal on purchasing assets from TIWA company (7 affirmative votes, 0 negative votes and 0 abstention) In order to further enrich the company's generic product line reserve, optimize product layout and effectively enhance the company's product competitiveness, the board of directors of the company decided to sign the authorization and distribution agreement with TIWA Pharmaceutical Industry Co., Ltd (hereinafter referred to as "TIWA") and carry out production technology transfer and other related work The investment is expected to be 160 million yuan Relevant contents are as follows: 1 Introduction to the counterparty: Teva Pharmaceutical Industries Limited Chinese Name: Israel TIWA Pharmaceutical Industry Co., Ltd main business: dedicated to research, development, production and promotion of specialty drugs, brand generic drugs and over-the-counter drugs 2、 Basic information of the transaction subject 1 Six products registered in China, including clopidogrel bisulfate tablets The basic information of the products shows that the above products are all clinical varieties, and the total domestic sales in 2017 was 14.89 billion yuan 2 Subject matter: ① exclusive sales agency of 6 products in China (except for Hong Kong, Macao and Taiwan), with a term of 20 years, which will be automatically renewed unless the agreement is terminated for some reason; ② relevant technical data of 6 products; ③ exclusive use of Tyva trademark to develop designated products in China (except for Hong Kong, Macao and Taiwan Bay) ④ TIWA helped the company to obtain the approval documents for domestic listing of six products in China 3 The price payment transaction amount is USD 15 million, which shall be paid by the company in stages according to the agreement Information source: enterprise announcement
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.